Clinical trial investigates oral MRGPRX2 antagonist in urticaria
Drug Discovery World
SEPTEMBER 4, 2024
The first patient has been treated in a Phase II trial of EVO756 in adults with chronic inducible urticaria (CIndU). “As we continue to execute on our clinical development plans for EVO756, we are commencing this Phase II trial in 15 study sites across the United States.
Let's personalize your content